The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans

International Angiology

Volumn 29, Issue 2 SUPPL. 1, 2010, Pages 49-54

  Matsumoto, T ^a   Iwasa, K ^a   Kyuragi, R ^a   Honma, K ^a   Guntani, A ^a   Ohmine, T ^a   Itoh, H ^a   Onohara, T ^a   Maehara, Y ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Beraprost sodium; Endothelin 1; Intermittent claudication

Indexed keywords

BERAPROST; ENDOTHELIN 1; N(G),N(G) DIMETHYLARGININE; NITRATE;

ANKLE BRACHIAL INDEX; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EXERCISE TEST; HUMAN; INTERMITTENT CLAUDICATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; VASODILATATION; WALKING;

ADMINISTRATION, ORAL; AGED; ANKLE BRACHIAL INDEX; ARGININE; ARTERIOSCLEROSIS OBLITERANS; BIOLOGICAL MARKERS; ENDOTHELIN-1; EPOPROSTENOL; EXERCISE TEST; EXERCISE TOLERANCE; HUMANS; INTERMITTENT CLAUDICATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS; WALKING;

EID: 77953607651     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation 1970;41:875-83.
2. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5.
3. Armstrong JM, Lattimer N, Moncada S, Vane JR. Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol 1978;62:125-30. (Pubitemid 8251906)
4. Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188-92.
5. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365. (Pubitemid 27197541)
6. Ono F, Nagaya N, Okumura H, Shimizu Y, Kyotani S, Nakanishi N et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003;123:1583-8.
7. Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996;27:788-93.
8. Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000;102:426-31.
9. Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003;41:1679-86.
10. Stein C, Classen HG, Schwedt G. Kinetic studies on nitrite and nitrate in rats by ion-pair chromatography. Clin Chim Acta 1988;175:167-73.
11. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al.; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endotihelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
12. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150-4.
13. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88(5 Pt 1):2149-55.
14. Fowkes FG. Epidemiology of atherosclerotic arterial disease in the lower limbs. Eur J Vasc Surg 1988;2:283-91.
15. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92.
16. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
17. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988;238:249-52.
18. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989;78:225-8. (Pubitemid 19195493)
19. Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994;269:11938-44. (Pubitemid 24196684)
20. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987;92:181-7. (Pubitemid 17134934)
21. Stamler J, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989;65:789-95. (Pubitemid 19226452)
22. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193-7. (Pubitemid 120016036)
23. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-6. (Pubitemid 29120084)
24. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000;20:2032-7.
25. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7. (Pubitemid 28509278)
26. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
27. Zoccali C. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif 2002;20:469-72.
28. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
29. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
30. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001;100:161-7.
31. Ohata S, Ishibashi Y, Shimada T, Takahashi N, Sugamori T, Sakane T et al. Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease. Clin Exp Pharmacol Physiol 2006;33:381-7.